Welcome to the Swiss Peritoneal Cancer Group
The Swiss Peritoneal Cancer Group (SPCG) was founded in June 2013 and two years later the group was accepted as a workgroup of the Swiss Society for Visceral Surgery (Schweizerische Gesellschaft für Viszeralchirurgie, SGVC). The SPCG provides a platform for surgeons, gynecologists and medical oncologists engaged in peritoneal malignancies, cytoreduction and HIPEC.
Swiss Peritoneal Cancer Group
The aims and tasks of the SPCG are:
- One meeting per year
- General assembly during the congress of the Swiss Society for Surgery (Schweizerische Gesellschaft für Chirurgie, SGC) or during a congress of the Swiss Society for Visceral Surgery (Schweizerische Gesellschaft für Viszeralchirurgie, SGVC)
- Establishing a Swiss registry for cytoreduction/HIPEC
- Organization and realization of a regular congress on cytoreduction/HIPEC in Switzerland
- Promotion of research in the field of cytoreduction/HIPEC
We are proud to present to you the current list of responsibilities in the SPCG.
Board member SGVC
Swiss Society of Visceral Surgery
The society aims to promote visceral surgery in cooperation with and within the Swiss Society of Surgery (Schweizerische Gesellschaft für Chirurgie, SGC). It deals primarily with health policy issues, professional policy aspects, problems and quality of education and training as well as certification requirements. The society represents the interests of visceral surgeons in professional organizations and in collective bargaining. The group collaborates with European professional societies with the same or similar interests and can join such societies as a member.
Friday, November 8th – Saturday, November 9th, 2019
Cantonal Hospital, St.Gallen/Switzerland,
Central Lecture Hall, Building 21
Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis.
Solass, W, Sempoux, C, Carr, N J, Bibeau, F, Neureiter, D, Jager, T, Di Caterino, T, Brunel, C, Klieser, E, Fristrup, C W, Mortensen, M B, Detlefsen, S.
Systemic inflammatory response after hyperthermic intraperitoneal chemotherapy (HIPEC): The perfusion protocol matters!
Roth, L, Eshmuminov, D, Laminger, F, Koppitsch, C, Schneider, M, Graf, T R, Gupta, A, Kober, F, Roka, S, Gertsch, P, Lehmann, K.
Long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases of urachal cancer.
Mertens, L S, Behrendt, M A, Mehta, A M, Stokkel, L, de Jong, J, Boot, H, Horenblas, S, van der Heijden, M S, Moonen, L M, Aalbers, A G J, Meinhardt, W, van Rhijn, B W G.
RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score.
Arjona-Sanchez, A, Rodriguez-Ortiz, L, Baratti, D, Schneider, M A, Gutierrez-Calvo, A, Garcia-Fadrique, A, Tuynman, J B, Cascales-Campos, P A, Martin, V C, Morales, R, Salti, G I, Arteaga, X, Pacheco, D, Alonso-Gomez, J, Yalkin, O, Villarejo-Campos, P, Sanchez-Hidalgo, J M, Casado-Adam, A, Cosano-Alvarez, A, Rufian-Pena, S, Briceno, J.
Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane) for peritoneal carcinomatosis – a phase I first-in-human study.
Van De Sande, L, Graversen, M, Hubner, M, Pocard, M, Reymond, M, Vaira, M, Cosyns, S, Willaert, W, Ceelen, W.
Inflammatory Response and Toxicity After Pressurized IntraPeritoneal Aerosol Chemotherapy.
Teixeira Farinha, H, Grass, F, Labgaa, I, Pache, B, Demartines, N, Hubner, M.
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naive upper gi-adenocarcinomas with peritoneal seeding – a phase II/III trial of the AIO/CAOGI/ACO.
Oliver Goetze, T, Al-Batran, S E, Pabst, U, Reymond, M, Tempfer, C, Bechstein, W O, Bankstahl, U, Gockel, I, Konigsrainer, A, Kraus, T, Monig, S P, Rau, B, Schwarzbach, M, Piso, P.
The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the “Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)”, the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.
Dueckelmann, A M, Fink, D, Harter, P, Heinzelmann, V, Marth, C, Mueller, M, Reinthaller, A, Tamussino, K, Wimberger, P, Sehouli, J.
The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).
Bushati, M, Rovers, K P, Sommariva, A, Sugarbaker, P H, Morris, D L, Yonemura, Y, Quadros, C A, Somashekhar, S P, Ceelen, W, Dube, P, Li, Y, Verwaal, V J, Glehen, O, Piso, P, Spiliotis, J, Teo, M C C, Gonzalez-Moreno, S, Cashin, P H, Lehmann, K, Deraco, M, Moran, B, de Hingh, I.
Impact of Pressurized Intraperitoneal Aerosol Chemotherapy on Quality of Life and Symptoms in Patients with Peritoneal Carcinomatosis: A Retrospective Cohort Study.
Teixeira Farinha, H, Grass, F, Kefleyesus, A, Achtari, C, Romain, B, Montemurro, M, Demartines, N, Hubner, M.
Major postoperative complications are a risk factor for impaired survival after CRS/HIPEC.
Schneider, M A, Eshmuminov, D, Lehmann, K.
Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis: A Retrospective Cohort Study.
Hubner, M, Teixeira Farinha, H, Grass, F, Wolfer, A, Mathevet, P, Hahnloser, D, Demartines, N.
Pressurized IntraPeritoneal Aerosol Chemotherapy – Practical aspects.
Hubner, M, Grass, F, Teixeira-Farinha, H, Pache, B, Mathevet, P, Demartines, N.
Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis.
Grass, F, Vuagniaux, A, Teixeira-Farinha, H, Lehmann, K, Demartines, N, Hubner, M.
Intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases: an updated systematic review.
El-Nakeep, S, Rashad, N, Oweira, H, Schmidt, J, Helbling, D, Giryes, A, Petrausch, U, Mehrabi, A, Decker, M, Abdel-Rahman, O.
To become a member
If you perform HIPEC or related procedures or if you are interested in the treatment of PSM or related procedures we would like to invite you to become a member of the group. As a member you can actively participate in the work of the SPCG and will be informed about the current developments and activities of the Group.
Since we are a workgroup of the SGVC, full membership can only be granted to members of the Swiss Society for Visceral Surgery or the Swiss Society for Surgery. Otherwise holders of an FMH-title or an FMH-equivalent title would be eligible for associate membership (“zugewandte Mitgliedschaft”).
If you are interested to become a member of the Swiss Peritoneal Cancer Group please fill out the form linked on register now and send it directly back per e-mail or to Tanja Burkard. Her contact details can be found below.
The membership fee of the Swiss Peritoneal Cancer Group will be included in the invoice for the membership fee of the Swiss Society for Visceral Surgery (SGVC).
In case you have any questions please do not hesitate to contact Tanja Burkard who will surely help you with your requests.
Kantonsspital St. Gallen
Klinik für Allgemein-, Viszeral-, Endokrin- und Transplantationschirurgie
CH-9007 St. Gallen
Phone: +41 71 494 1344